ERA Banner
Download Add to Cart Share
More Like This
  • Treatment of Gastric Cancer With Peritoneal Carcinomatosis by Cytoreductive Surgery and HIPEC: A Systematic Review of Survival, Mortality, and Morbidity
  • Gill, Richdeep S.
    Al-Adra, David P.
    Nagendran, Jeevan
    Campbell, Sandy
    Shi, Xinzhe
    Haase, Erika
    Schiller, Daniel
  • Articles
    gastric cancer
    cytoreductive surgery
    peritoneal carcinomatosis
  • Journal Article (Published)
  • English
  • Adobe PDF
  • Gastric cancer with peritoneal carcinomatosis has an extremely poor prognosis, which may be improved with cytoreductive surgery (CRS) combined with heated intraperitoneal chemotherapy (HIPEC). We systematically reviewed the literature regarding the efficacy of CRS þ HIPEC in these patients. Electronic databases were searched from 2000 to 2010. Following CRS þ HIPEC, overall median survival was 7.9 months and improved to 15 months for patients with completeness of cytoreduction scores of 0/1, however with a 30-day mortality rate of 4.8%. This is the pre-peer reviewed version of the following article: Gill RS, Al-Adra DP, Nagendran J, Campbell S, Shi X, Haase E, Schiller D. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: A systematic review of survival, mortality, and morbidity.J Surg Oncol. 2011 Jun 28. doi: 10.1002/jso.22017. , which has been published in final form at 10.1002/jso.22017.
  • 10.1002/jso.22017